ARWR
Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR)
Article Summary
BUY- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) surged 18% after announcing positive Phase 3 SHASTA-3 and SHasTA-4 clinical trials evaluating plozasiran in patients with severe hypertriglyceridemia, with both studies meeting primary endpoint of reducing triglyceride levels compared with placebo and achieving every prespecified secondary endpoint.
- Patients receiving 25 mg subcutaneous injection once every three months experienced median triglyceride reductions of 79% in SHASA-3 versus 81% inSHASTA 4 after 12 months, while the placebo group recorded reductions of approximately 27%.
- Pre-planned pooled analysis of both trials also demonstrated statistically significant reduction in acute pancreatitis events among patients treated with ploz as compared with those receiving placebo, with no new safety concerns identified and no clinically meaningful differences observed in routine laboratory testing.
- Arrowhead Pharmaceuticals plans to submit supplemental New Drug Application (sNDA) to U.S.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 14.1% | 25% | 50.0 ptsMeets Minimum (14.1%) - Passes screener |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 8.4% | 20% | 35.0 ptsBelow Screener (8.4%) - Target: $97.10 vs Current: $89.57 |
| Gross Margin % ? | 95.9% | 15% | 100.0 ptsExceptional (95.9%) - Strong pricing power |
| Drawdown from 52-Wk High ? | 2.0% | 15% | 20.0 ptsBarely a Dip (2.0%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About ARWR
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
- Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
- The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy.
- In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials.
- The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc.
- Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.